Phillip Frost Acquires $403789 Worth of OPKO Health, Inc. (OPK) Shares; Shorts at MICROPORT SCIENTIFIC ORDINARY SHAR (MCRPF) Lowered By 0.57%

May 21, 2018 - By Marie Mckinney

MICROPORT SCIENTIFIC CORP ORDINARY SHAR (OTCMKTS:MCRPF) had a decrease of 0.57% in short interest. MCRPF’s SI was 2.03 million shares in May as released by FINRA. Its down 0.57% from 2.04M shares previously. With 13,600 avg volume, 149 days are for MICROPORT SCIENTIFIC CORP ORDINARY SHAR (OTCMKTS:MCRPF)’s short sellers to cover MCRPF’s short positions. The stock increased 3.70% or $0.05 during the last trading session, reaching $1.4. About shares traded. MicroPort Scientific Corporation (OTCMKTS:MCRPF) has 0.00% since May 21, 2017 and is . It has underperformed by 11.55% the S&P500.

Since January 22, 2018, it had 53 insider purchases, and 0 selling transactions for $11.12 million activity. Another trade for 55,000 shares valued at $236,680 was made by FROST PHILLIP MD ET AL on Friday, February 2. Logal Adam also bought $7,011 worth of OPKO Health, Inc. (NASDAQ:OPK) on Tuesday, March 13. Shares for $19,500 were bought by Rubin Steven D on Wednesday, March 7. On Wednesday, April 25 the insider Fishel Robert Scott bought $37,125.

The stock decreased 18.24% or $0.89 during the last trading session, reaching $3.99. About 19.09 million shares traded or 270.18% up from the average. OPKO Health, Inc. (NASDAQ:OPK) has declined 60.81% since May 21, 2017 and is downtrending. It has underperformed by 72.36% the S&P500.

Investors sentiment decreased to 0.84 in Q4 2017. Its down 0.30, from 1.14 in 2017Q3. It dropped, as 32 investors sold OPKO Health, Inc. shares while 60 reduced holdings. 24 funds opened positions while 53 raised stakes. 119.15 million shares or 0.51% less from 119.76 million shares in 2017Q3 were reported. Lpl Financial Ltd Liability holds 0% of its portfolio in OPKO Health, Inc. (NASDAQ:OPK) for 13,374 shares. Oppenheimer Inc reported 15,664 shares stake. 5,000 are owned by Bessemer Gp Inc. Stevens Mgmt Lp reported 271,566 shares. Hartline Invest Corporation invested in 20,634 shares. Mivtachim The Workers Social Ins Fund (Under Special Management) invested in 2.58M shares. Bank Of Ny Mellon, a New York-based fund reported 1.36M shares. Royal Fincl Bank Of Canada accumulated 0% or 118,650 shares. Pictet Asset Limited stated it has 282,000 shares. Raymond James And holds 0% or 332,514 shares. Shufro Rose & Co Ltd Company accumulated 186,000 shares or 0.09% of the stock. Utd Cap Advisers Llc invested in 0% or 29,664 shares. Zurcher Kantonalbank (Zurich Cantonalbank) owns 16,952 shares. Prudential Financial stated it has 24,511 shares. Citigroup Incorporated reported 689,764 shares or 0% of all its holdings.

More notable recent OPKO Health, Inc. (NASDAQ:OPK) news were published by: which released: “Better Buy: Opko Health, Inc. (OPK) vs. Myriad Genetics (MYGN)” on May 18, 2018, also with their article: “Here’s Why OPKO Health Dropped as Much as 23% Today” published on May 18, 2018, published: “OPKO Health Reports First Quarter 2018 Financial Results” on May 08, 2018. More interesting news about OPKO Health, Inc. (NASDAQ:OPK) were released by: and their article: “OPKO Plans to Address Draft Local Coverage Determination Published by Novitas Solutions for 4Kscore Test” published on May 18, 2018 as well as‘s news article titled: “Cantor Fitzgerald: 18 Drug Companies With Catalysts Worth Watching” with publication date: May 19, 2018.

The Opko Health Inc’s CEO & Chairman Phillip Frost invested in – 100,000 shares of Opko Health Inc, based on the average price of $4.0 of a share . This purchase of shares recently had a value of approx. $403,789 U.S Dollars . This is not his first insider trade, in the last month, he purchased another 531,524 shares worth $1.63 million USD. This investment was reported on 21-05-2018 and is already filed with the Security Exchange Commission. The source report is available for free to the public here. Currently, Phillip Frost holds a total of 191.09 million shares or 34.16% of Opko Health Inc’s total market cap.

Analysts await OPKO Health, Inc. (NASDAQ:OPK) to report earnings on August, 14. They expect $-0.07 EPS, down 75.00% or $0.03 from last year’s $-0.04 per share. After $-0.08 actual EPS reported by OPKO Health, Inc. for the previous quarter, Wall Street now forecasts -12.50% EPS growth.

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, and Mexico. The company has market cap of $2.23 billion. The company's Diagnostics segment operates Bio-Reference Laboratories, a clinical laboratory that offers laboratory testing services in the detection, diagnosis, evaluation, monitoring, and treatment of diseases. It currently has negative earnings. The Bio-Reference Laboratories also provides core genetic testing and leverage products, such as the 4Kscore prostate cancer test and the Claros 1 in-office immunoassay platform.

OPKO Health, Inc. (NASDAQ:OPK) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Marie Mckinney

Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: